+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Multiple Sclerosis Drugs Market 2019-2023 - Product Image

Global Multiple Sclerosis Drugs Market 2019-2023

  • ID: 4758156
  • Report
  • February 2019
  • Region: Global
  • 110 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Bayer AG
  • Biogen
  • Merck KGaA
  • Novartis AG
  • Sanofi
  • MORE
Globally, the prevalence of multiple sclerosis has increased due to genetic and environmental factors. Another reason which could be attributed to the increasing prevalence is the advances in diagnostic techniques in this therapy area. The prevalence of autoimmune diseases such as type 1 diabetes and certain infections such as infectious mononucleosis also increases the risk of multiple sclerosis. In 2008, the global prevalence of multiple sclerosis was estimated to be 0.031%, which increased to 0.032% in 2013. The prevalence of multiple sclerosis in Europe is also high. High disease prevalence drives the demand for drugs, thereby driving the growth of the market. The analysts have predicted that the multiple sclerosis drugs market will register a CAGR of close to 6% by 2023.

Market Overview

Strong drug pipeline

With the increase in the prevalence of multiple sclerosis, there is a high unmet need for a strong pipeline of disease-modifying drugs. Current drugs for multiple sclerosis slow down the disease progression, but in many patients' responses to drugs are often variable and suboptimal. Ongoing R&D for the development of new drugs has resulted in the development of a strong drug pipeline for the treatment of multiple sclerosis. Therefore, the drug development initiatives by companies are expected to dive the market in the forecast period.

Side effects of multiple sclerosis drugs

The side effects associated with multiple sclerosis drugs can range from mild to serious. Therefore, side effects associated with these drugs can lead to low patient compliance and may hinder the growth of the global multiple sclerosis drugs market.

For the detailed list of factors that will drive and challenge the growth of the multiple sclerosis drugs market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be moderately concentrated and with the presence of limited vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bayer AG
  • Biogen
  • Merck KGaA
  • Novartis AG
  • Sanofi
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: PIPELINE ANALYSIS
  • Pipeline analysis
PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 07: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Oral - Market size and forecast 2018-2023
  • Parenteral - Market size and forecast 2018-2023
  • Market opportunity by type
PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS
  • Market trends
PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer AG
  • Biogen
  • Merck KGaA
  • Novartis AG
  • Sanofi
PART 15: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Global central nervous system (CNS) disorders drugs market
Exhibit 02: Segments of global central nervous system (CNS) disorders drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline drugs in late-stage clinical trials
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Oral - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Oral - Year-over-year growth 2019-2023 (%)
Exhibit 22: Parenteral - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Parenteral - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 34: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: Bayer AG - Vendor overview
Exhibit 45: Bayer AG - Business segments
Exhibit 46: Bayer AG - Organizational developments
Exhibit 47: Bayer AG - Geographic focus
Exhibit 48: Bayer AG - Segment focus
Exhibit 49: Bayer AG - Key offerings
Exhibit 50: Biogen - Vendor overview
Exhibit 51: Biogen - Business segments
Exhibit 52: Biogen - Organizational developments
Exhibit 53: Biogen - Geographic focus
Exhibit 54: Biogen - Key offerings
Exhibit 55: Merck KGaA - Vendor overview
Exhibit 56: Merck KGaA - Business segments
Exhibit 57: Merck KGaA - Organizational developments
Exhibit 58: Merck KGaA - Geographic focus
Exhibit 59: Merck KGaA - Segment focus
Exhibit 60: Merck KGaA - Key offerings
Exhibit 61: Novartis AG - Vendor overview
Exhibit 62: Novartis AG - Business segments
Exhibit 63: Novartis AG - Organizational developments
Exhibit 64: Novartis AG - Geographic focus
Exhibit 65: Novartis AG - Segment focus
Exhibit 66: Novartis AG - Key offerings
Exhibit 67: Sanofi - Vendor overview
Exhibit 68: Sanofi - Business segments
Exhibit 69: Sanofi - Organizational developments
Exhibit 70: Sanofi - Geographic focus
Exhibit 71: Sanofi - Segment focus
Exhibit 72: Sanofi - Key offerings
Exhibit 73: Validation techniques employed for market sizing
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Bayer AG
  • Biogen
  • Merck KGaA
  • Novartis AG
  • Sanofi
  • MORE
Global Multiple Sclerosis Drugs Market 2019-2023

The analyst recognizes the following companies as the key players in the global multiple sclerosis drugs market: Bayer AG, Biogen, Merck KGaA, Novartis AG, Sanofi.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the introduction of favorable reimbursement policies.”

According to the report, one of the major drivers for this market is the rising prevalence of multiple sclerosis has increased due to genetic and environmental factors.

Further, the report states that one of the major factors hindering the growth of this market is the challenges associated with diagnosis of multiple sclerosis.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Bayer AG
  • Biogen
  • Merck KGaA
  • Novartis AG
  • Sanofi
Note: Product cover images may vary from those shown
Adroll
adroll